



HYPHENS PHARMA INTERNATIONAL LIMITED

(Company Registration No. 201735688C)
(Incorporated in the Republic of Singapore)

BUSINESS CONTINUITY DURING COVID-19 PANDEMIC

The Board of Directors of Hyphens Pharma International Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) wishes to update our shareholders on the Group’s operations in the current period in view of COVID-19.

Singapore’s Multi-Ministry Taskforce has announced heightened safe distancing measures as a circuit breaker to contain the spread of COVID-19 for the period from 7 April 2020 to 4 May 2020. As part of these measures, most physical workplace premises have been closed and only essential services that support daily needs remain open with safe-distancing measures in place.

Pan-Malayan Pharmaceuticals Pte Ltd (“**Pan-Malayan**”), a wholly-owned subsidiary of the Company, has obtained approval for an exemption from suspension of business activities during the circuit breaker period as the medical wholesale and distribution business is considered as part of the essential supply chain to support healthcare services. Medical establishments can continue to place orders with Pan-Malayan and deliveries will be fulfilled by our alternating operations teams on site while sales and administrative staff will support from home. The Group has taken the necessary steps to ensure compliance with the advisories issued by the various government agencies while continuing with its business operations in Singapore.

In the countries that the Group has direct operations in, namely Indonesia, Malaysia, the Philippines and Vietnam, our local distributors in each respective country will similarly continue to operate and supply to medical establishments and pharmacies, while complying with the respective country’s legal requirements and social distancing measures.

BY ORDER OF THE BOARD

Lim See Wah

Executive Chairman and Chief Executive Officer

9 April 2020

*This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor, DBS Bank Ltd. (“**Sponsor**”) for compliance with the Singapore Exchange Securities Trading Limited (“SGX-ST”) Listing Manual Section B: Rules of Catalyst. The Sponsor has not verified the contents of this announcement.*

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact persons for the Sponsor are Ms Heng Mui Mui, Managing Director, and Mr Kelvin Wong, Senior Vice President, who can be contacted at 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone: +65 6878 8888.